P Worth Longest1,2, Geng Tian1, Navvab Khajeh-Hosseini-Dalasm1, Michael Hindle2. 1. 1 Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University , Richmond, Virginia. 2. 2 Department of Pharmaceutics, Virginia Commonwealth University , Richmond, Virginia.
Abstract
BACKGROUND: The objective of this study was to compare aerosol deposition predictions of a new whole-airway CFD model with available in vivo data for a dry powder inhaler (DPI) considered across multiple inhalation waveforms, which affect both the particle size distribution (PSD) and particle deposition. METHODS: The Novolizer DPI with a budesonide formulation was selected based on the availability of 2D gamma scintigraphy data in humans for three different well-defined inhalation waveforms. Initial in vitro cascade impaction experiments were conducted at multiple constant (square-wave) particle sizing flow rates to characterize PSDs. The whole-airway CFD modeling approach implemented the experimentally determined PSDs at the point of aerosol formation in the inhaler. Complete characteristic airway geometries for an adult were evaluated through the lobar bronchi, followed by stochastic individual pathway (SIP) approximations through the tracheobronchial region and new acinar moving wall models of the alveolar region. RESULTS: It was determined that the PSD used for each inhalation waveform should be based on a constant particle sizing flow rate equal to the average of the inhalation waveform's peak inspiratory flow rate (PIFR) and mean flow rate [i.e., AVG(PIFR, Mean)]. Using this technique, agreement with the in vivo data was acceptable with <15% relative differences averaged across the three regions considered for all inhalation waveforms. Defining a peripheral to central deposition ratio (P/C) based on alveolar and tracheobronchial compartments, respectively, large flow-rate-dependent differences were observed, which were not evident in the original 2D in vivo data. CONCLUSIONS: The agreement between the CFD predictions and in vivo data was dependent on accurate initial estimates of the PSD, emphasizing the need for a combination in vitro-in silico approach. Furthermore, use of the AVG(PIFR, Mean) value was identified as a potentially useful method for characterizing a DPI aerosol at a constant flow rate.
BACKGROUND: The objective of this study was to compare aerosol deposition predictions of a new whole-airway CFD model with available in vivo data for a dry powder inhaler (DPI) considered across multiple inhalation waveforms, which affect both the particle size distribution (PSD) and particle deposition. METHODS: The Novolizer DPI with a budesonide formulation was selected based on the availability of 2D gamma scintigraphy data in humans for three different well-defined inhalation waveforms. Initial in vitro cascade impaction experiments were conducted at multiple constant (square-wave) particle sizing flow rates to characterize PSDs. The whole-airway CFD modeling approach implemented the experimentally determined PSDs at the point of aerosol formation in the inhaler. Complete characteristic airway geometries for an adult were evaluated through the lobar bronchi, followed by stochastic individual pathway (SIP) approximations through the tracheobronchial region and new acinar moving wall models of the alveolar region. RESULTS: It was determined that the PSD used for each inhalation waveform should be based on a constant particle sizing flow rate equal to the average of the inhalation waveform's peak inspiratory flow rate (PIFR) and mean flow rate [i.e., AVG(PIFR, Mean)]. Using this technique, agreement with the in vivo data was acceptable with <15% relative differences averaged across the three regions considered for all inhalation waveforms. Defining a peripheral to central deposition ratio (P/C) based on alveolar and tracheobronchial compartments, respectively, large flow-rate-dependent differences were observed, which were not evident in the original 2D in vivo data. CONCLUSIONS: The agreement between the CFD predictions and in vivo data was dependent on accurate initial estimates of the PSD, emphasizing the need for a combination in vitro-in silico approach. Furthermore, use of the AVG(PIFR, Mean) value was identified as a potentially useful method for characterizing a DPI aerosol at a constant flow rate.
Entities:
Keywords:
computational fluid dynamics (CFD); pharmaceutical aerosols; predictions of aerosol deposition; respiratory drug delivery; stochastic individual pathway model
Authors: Jessica M Oakes; Alison L Marsden; Celine Grandmont; Shawn C Shadden; Chantal Darquenne; Irene E Vignon-Clementel Journal: Ann Biomed Eng Date: 2013-12-07 Impact factor: 3.934
Authors: Stephen Newman; William D Bennett; Martyn Biddiscombe; Sunalene G Devadason; Myrna B Dolovich; John Fleming; Sabine Haeussermann; Claudius Kietzig; Philip J Kuehl; Beth L Laube; Knut Sommerer; Glyn Taylor; Omar S Usmani; Kirby L Zeman Journal: J Aerosol Med Pulm Drug Deliv Date: 2012-12 Impact factor: 2.849
Authors: Elizabeth L Perkins; Saikat Basu; Guilherme J M Garcia; Robert A Buckmire; Rupali N Shah; Julia S Kimbell Journal: Otolaryngol Head Neck Surg Date: 2017-11-21 Impact factor: 3.497
Authors: Karl Bass; Susan Boc; Michael Hindle; Kelley Dodson; Worth Longest Journal: J Aerosol Med Pulm Drug Deliv Date: 2018-12-15 Impact factor: 2.849
Authors: P Worth Longest; Karl Bass; Rabijit Dutta; Vijaya Rani; Morgan L Thomas; Ahmad El-Achwah; Michael Hindle Journal: Expert Opin Drug Deliv Date: 2018-12-10 Impact factor: 6.648
Authors: Lauren F Tracy; Saikat Basu; Parth V Shah; Dennis O Frank-Ito; Snigdha Das; Adam M Zanation; Julia S Kimbell Journal: Int Forum Allergy Rhinol Date: 2019-03-12 Impact factor: 3.858
Authors: A P Kuprat; M Jalali; T Jan; R A Corley; B Asgharian; O Price; R K Singh; S Colby; C Darquenne Journal: J Aerosol Sci Date: 2020-08-15 Impact factor: 3.433